#United States #healthcare #Zurich #BC Platforms #OmicsBank

BC Platforms and OmicsBank's Strategic Partnership

BC Platforms, a pioneer in healthcare data analytics, has entered into a strategic alliance with OmicsBank, a leading data infrastructure company, to foster improved access to expansive real-world and multi-omics datasets from India and the United Arab Emirates (UAE). This collaboration not only amplifies BC Platforms' existing global data network but also enhances the accessibility of crucial patient data across these growing markets.

Founded with a mission to empower healthcare innovation, BC Platforms specializes in utilizing advanced analytics to process complex datasets for precise medical outcomes. The recent partnership is set to significantly broaden their patient base, incorporating over 12 million patient lives from India and around 500,000 from the UAE. With future expansions planned, additional data from regions like Saudi Arabia, Taiwan, the Philippines, and Malaysia will be integrated, making this collaboration a vital component in improving healthcare solutions globally.

Expanding Access to Multi-Omics Data

The OmicsBank collaboration is revolutionary, providing extensive datasets that include millions of electronic medical records (EMRs), pathology slides, medical images, and a wealth of sequencing data. These resources can be configured as custom datasets aligned with specific research needs or as expansive longitudinal cohorts useful for a variety of healthcare analytics. This flexibility enables better development and validation of AI models, creating a significant step forward in personalized medicine and broader healthcare research.

Integrating this data into BC Platforms' innovative agentic-AI data mastering platform, BC Unify, will facilitate seamless harmonization and access through tools like BC Mosaic (which creates federated trusted research environments) and BC Catalyst (which focuses on insights and predictive analytics). These advancements support various healthcare professionals and researchers from the early stages of discovery all the way through clinical development and market proof.

Insights from Leadership

Mukhtar Ahmed, the CEO of BC Platforms, highlights the partnership's importance, stating, "India’s rich diversity in disease and its ever-growing significance in clinical research is a goldmine for life science companies. By partnering with OmicsBank, we are ensuring access to invaluable research-ready data, enabling companies to effectively develop targeted therapies that address the needs of diverse patient populations globally."

On the other hand, Sumit Sinha, CEO of OmicsBank, expressed, "Our goal has always been to provide an AI-ready data infrastructure that responsibly transforms fragmented data into usable datasets for global life sciences research. Partnering with BC Platforms will enhance our capabilities and ensure more inclusive representation of diverse patient populations in drug development processes."

The Importance of India in Global Drug Development

India, housing nearly 20% of the world’s population, is uniquely positioned in the global healthcare landscape yet has been underrepresented in global genetic studies. Currently, South Asian populations account for around 2% of participants in genome-wide association studies, which does not reflect the true diversity of diseases and health paradigms present in the region.

With a high burden of non-communicable diseases such as cardiovascular issues, diabetes, and cancer, India presents a vital market for medical research and therapeutic development. The collaboration between BC Platforms and OmicsBank will serve to fill existing gaps in large-scale analytics and AI application in healthcare, ultimately improving feasibility assessments and enhancing efficiency throughout the drug lifecycle.

As BC Platforms continues to expand its reach, accessibility to high-quality patient datasets becomes increasingly crucial. By integrating diverse data, researchers can minimize biases and approach drug development with a more global perspective.

Expanding Global Reach

With the OmicsBank alliance, BC Platforms has successfully extended its global patient catchment to surpass 187 million lives across over 35 countries, significantly boosting its data capabilities beyond the U.S. This expansion covers critical therapeutic areas, including oncology, cardiometabolic conditions, neurology, and rare diseases, thus accelerating research and evidence generation across the lifecycle of drug development.

Conclusion

BC Platforms is committed to advancing healthcare technology and analytics, and the partnership with OmicsBank exemplifies this commitment. Together, they aim to accelerate innovation and foster a deeper understanding of diverse patient needs, ultimately creating a stronger foundation for future medical advancements. By harnessing the power of comprehensive, research-ready datasets, they are poised to significantly influence global healthcare practices.

For further insights, explore more at BC Platforms and OmicsBank.